The role of artificial cells in the fight against COVID-19: deliver vaccine, hemoperfusion removes toxic cytokines, nanobiotherapeutics lower free radicals and pCO 2 and replenish blood supply
Open Access
- 3 October 2022
- journal article
- research article
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 50 (1) , 240-251
Abstract
This review concentrates on how artificial cells can contribute to helping patients with COVID-19. Artificial cells have led to mRNA vaccines with more improvements to come. Excessive cytokines in severe COVID-19 can damage organs leading to death. Artificial cell-based collodion macroporous activated charcoal adsorbent can effectively remove middle molecular weight range molecules in patients. A novel hemoperfusion device based on collodion membrane macroporous synthetic resin effectively removes cytokines and recovery in COVID-19 patients. This has been approved as an emergency treatment for COVID-19 in China, Europe, and Canada. A recent nanobiotherapeutic containing haemoglobin and up to six times the concentration of red blood cell enzymes: catalase, superoxide dismutase and carbonic anhydrase. In an animal study, this can effectively lower the damaging increase in free radicals and the removal of increased tissue pCO2. This can also help as blood substitute for the severe and critical problem of COVID-19 pandemic donor blood supply crisis.Keywords
This publication has 42 references indexed in Scilit:
- Early detection of cardiac ischemia using a conductometric pCO2sensor: real-time drift correction and parameterizationPhysiological Measurement, 2010
- Development of Resin Adsorbents for Blood Purification at Nankai University in ChinaArtificial Cells, Blood Substitutes, and Biotechnology, 2010
- Human Polymerized Hemoglobin for the Treatment of Hemorrhagic Shock when Blood Is Unavailable: The USA Multicenter TrialJournal of the American College of Surgeons, 2009
- Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cellsBlood, 2006
- Recent advances with liposomes as pharmaceutical carriersNature Reviews Drug Discovery, 2005
- Modified Hemoglobin Solution, with Desired Pharmacological Properties, Does not Activate Nuclear Transcription Factor NF-kappa B in Human Vascular Endothelial CellsArtificial Cells, Blood Substitutes, and Biotechnology, 1997
- Crosslinked Hemoglobin-Superoxide Dismutase-Catalase Scavenges Free Radicals in a Rat Model of Intestinal Ischemia-Reperfusion InjuryArtificial Cells, Blood Substitutes, and Biotechnology, 1997
- Stablisation of enzymes by microencapsulation with a concentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehydeBiochemical and Biophysical Research Communications, 1971
- Resting and action potentials in experimental bimolecular lipid membranesJournal of Theoretical Biology, 1968
- Diffusion of univalent ions across the lamellae of swollen phospholipidsJournal of Molecular Biology, 1965